Skip to main content
. 2018 Feb 1;9(1):17–30. doi: 10.14336/AD.2017.0230

Figure 7. Integrated model to define the role of PARP-1 inhibition in the type 2 diabetes related pathway.

Figure 7.

Olaparib treatment increases the expression of TCF7L2, GCG and PC1, thereby enhancing GLP-1 secretion in the endoendocrine L type gastrointestinal cells and subsequently promoting insulin secretion in the pancreatic β-cell.